149 related articles for article (PubMed ID: 1612530)
1. Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density.
Perrone G; Galoppi P; Valente M; Capri O; D'Ubaldo C; Anelli G; Zichella L
Gynecol Obstet Invest; 1992; 33(3):168-71. PubMed ID: 1612530
[TBL] [Abstract][Full Text] [Related]
2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis.
Tekeoğlu I; Adak B; Budancamanak M; Demirel A; Ediz L
Rheumatol Int; 2005 Dec; 26(2):157-61. PubMed ID: 15660234
[TBL] [Abstract][Full Text] [Related]
4. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.
Overgaard K
Calcif Tissue Int; 1994 Aug; 55(2):82-6. PubMed ID: 7953984
[TBL] [Abstract][Full Text] [Related]
5. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
[TBL] [Abstract][Full Text] [Related]
6. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
7. Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study.
Gürlek A; Bayraktar M; Gedik O
Calcif Tissue Int; 1997 Jul; 61(1):39-43. PubMed ID: 9192511
[TBL] [Abstract][Full Text] [Related]
8. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
Reginster JY; Denis D; Deroisy R; Lecart MP; De Longueville M; Zegels B; Sarlet N; Noirfalisse P; Franchimont P
J Bone Miner Res; 1994 Jan; 9(1):69-73. PubMed ID: 8154311
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
Reginster JY; Deroisy R; Lecart MP; Sarlet N; Zegels B; Jupsin I; de Longueville M; Franchimont P
Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
[TBL] [Abstract][Full Text] [Related]
10. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.
Nielsen NM; von der Recke P; Hansen MA; Overgaard K; Christiansen C
Calcif Tissue Int; 1994 Jul; 55(1):8-11. PubMed ID: 7922794
[TBL] [Abstract][Full Text] [Related]
11. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
Thamsborg G; Jensen JE; Kollerup G; Hauge EM; Melsen F; Sorensen OH
Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness of intranasal salmon calcitonin treatment in postmenopausal osteoporosis].
Kopaliani M
Georgian Med News; 2005 Apr; (121):38-42. PubMed ID: 15908722
[TBL] [Abstract][Full Text] [Related]
13. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
Plosker GL; McTavish D
Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
[TBL] [Abstract][Full Text] [Related]
14. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.
Gennari C; Agnusdei D; Montagnani M; Gonnelli S; Civitelli R
Calcif Tissue Int; 1992 Apr; 50(4):381-3. PubMed ID: 1571851
[TBL] [Abstract][Full Text] [Related]
15. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
Ellerington MC; Hillard TC; Whitcroft SI; Marsh MS; Lees B; Banks LM; Whitehead MI; Stevenson JC
Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
[TBL] [Abstract][Full Text] [Related]
16. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
Overgaard K; Hansen MA; Nielsen VA; Riis BJ; Christiansen C
Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
[TBL] [Abstract][Full Text] [Related]
17. [Salmon calcitonin in osteoporosis. The effect of intranasal application on bone mineral content and fracture frequency in postmenopausal women with manifest osteoporotic changes].
Overgaard K; Ravn P; Hansen MA; Christiansen C
Ugeskr Laeger; 1993 Aug; 155(31):2387-91. PubMed ID: 8346588
[TBL] [Abstract][Full Text] [Related]
18. Salmon calcitonin in the prevention of bone loss at perimenopause.
Arnala I; Saastamoinen J; Alhava EM
Bone; 1996 Jun; 18(6):629-32. PubMed ID: 8806006
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin load test to assess the efficacy of salmon calcitonin.
Stepan JJ; Zikán V
Clin Chim Acta; 2003 Oct; 336(1-2):49-55. PubMed ID: 14500034
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin.
Silverman SL
Rheum Dis Clin North Am; 2001 Feb; 27(1):187-96. PubMed ID: 11285994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
